| Name | Title | Contact Details |
|---|
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.
LifeStream Behavioral Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. LifeStream Behavioral Center is based in Leesburg, FL. You can find more information on LifeStream Behavioral Center at www.lsbc.net
Established in 1933, the American Board of Medical Specialties (ABMS), a not-for-profit organization comprising 24 medical specialty Member Boards, is the pre-eminent entity overseeing the certification of physician specialists in the United States. The primary function of ABMS is to assist its Member Boards in developing and implementing educational and professional standards to evaluate and certify physician specialists. By participating in these initiatives, ABMS also serves as a unique and highly influential voice in the healthcare industry, bringing focus and rigor to issues involving specialization and certification in medicine. ABMS is a designated primary equivalent source of credential information.
The Adjuvant Group is a Scotch Plains, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Amax NutraSource is a Eugene, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.